scispace - formally typeset
L

Leonard H. Wexler

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  157
Citations -  13518

Leonard H. Wexler is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Rhabdomyosarcoma & Sarcoma. The author has an hindex of 48, co-authored 144 publications receiving 10923 citations. Previous affiliations of Leonard H. Wexler include Children's National Medical Center & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Tumour exosome integrins determine organotropic metastasis

TL;DR: It is demonstrated that exosomes from mouse and human lung-, liver- and brain-tropic tumour cells fuse preferentially with resident cells at their predicted destination, namely lung fibroblasts and epithelial cells, liver Kupffer cells and brain endothelial cells.
Journal ArticleDOI

Age, thymopoiesis, and CD4+ t-lymphocyte regeneration after intensive chemotherapy

TL;DR: Thymus-dependent regeneration of CD4+ T lymphocytes occurs primarily in children, whereas even young adults have deficiencies in this pathway, and the results suggest that rapid T-cell regeneration requires residual thymic function in patients receiving high-dose chemotherapy.
Journal ArticleDOI

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Ayuko Hoshino, +136 more
- 20 Aug 2020 - 
TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.
Journal ArticleDOI

Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy

TL;DR: Thymic-independent pathways of T-cell regeneration appear to rapidly regenerate substantial numbers of CD8+, but not CD4+ T cells, resulting in prolonged T- cell subset imbalance after T-cells depletion, which has significant implications for immunotherapeutic strategies undertaken to eradicate minimal residual neoplastic disease after cytoreductive chemotherapy.
Journal ArticleDOI

Lymphocyte depletion during treatment with intensive chemotherapy for cancer.

TL;DR: Based on the history of opportunistic complications in patients with other disorders who display similar degrees of CD4+ T-cell lymphopenia and preliminary observations in this population, immune incompetence could surface as a dose-limiting toxicity for highly dose-intensive chemotherapy regimens.